GAMMA ANTY-D ® 50
Immunotherapy in serological conflict (e.g., Rh disease)
ApprovedCommercial
Key Facts
Indication
Immunotherapy in serological conflict (e.g., Rh disease)
Phase
Approved
Status
Commercial
Company
About Synthaverse
Synthaverse is a modern, dynamically developing Polish biotech that leverages its expertise and proprietary technologies to develop and deliver solutions shaping global health. The company has a diversified portfolio of commercial and development-stage products, primarily in immunotherapy, and supports its innovation through close cooperation with scientific centers. Its ambition is to push the boundaries of medicine while maintaining a strong focus on contract manufacturing and laboratory reagents. Led by CEO Mieczysław Starkowicz, the company combines decades of experience with a forward-looking approach to research and production.
View full company profileTherapeutic Areas
Other Immunotherapy in serological conflict (e.g., Rh disease) Drugs
| Drug | Company | Phase |
|---|---|---|
| GAMMA ANTY-D ® 150 | Synthaverse | Approved |